RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics, announces that Lisa A. Miller has been appointed Vice President and General Manager of Precision Medicine. She will drive the commercial strategy and execution for the company’s Precision Medicine business.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7989d9b1-18ad-4f2a-8cab-f7749ce0b402
"Our metabolomics technology has a tremendous role to play in realizing the promise of precision medicine for patients,” said Darin Leigh, Chief Commercial Officer at Metabolon. “Precision medicine is a key growth opportunity for our company, and Lisa’s leadership experience in life science and diagnostics commercialization will help us provide several innovative products to physicians in 2016.”
Ms. Miller has over 25 years of experience delivering commercial and operational success in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets. She is the former President and Chief Executive Officer of Prometheus Laboratories, Inc., a Nestlé Health Science company. While there, one of her key accomplishments was to lead the new product development and diagnostic portfolio expansion initiatives across all of the strategic health science platforms. Prior to Prometheus, she held senior commercial leadership positions at Dako (an Agilent Technologies company), Invitrogen and Thermo Fisher Scientific.
About Metabolon
Metabolon, Inc. is the world’s leading health technology company focused on metabolomics – a powerful tool for assessing health. Its proprietary platforms and informatics are delivering biomarker discoveries, innovative diagnostic tests, breakthroughs in precision medicine, and ground-breaking partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 4,000 independent and collaborative studies, resulting in over 500 peer-reviewed publications. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.